vs
Side-by-side financial comparison of FRIEDMAN INDUSTRIES INC (FRD) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
FRIEDMAN INDUSTRIES INC is the larger business by last-quarter revenue ($168.0M vs $86.8M, roughly 1.9× IOVANCE BIOTHERAPEUTICS, INC.). On growth, FRIEDMAN INDUSTRIES INC posted the faster year-over-year revenue change (78.6% vs 17.7%). FRIEDMAN INDUSTRIES INC produced more free cash flow last quarter ($-6.3M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 13.3%).
Hellman & Friedman (H&F) is an American private equity firm founded in 1984 by Warren Hellman and Tully Friedman that makes investments primarily through leveraged buyouts as well as growth capital investments. It has focused its efforts on several core target industries including media, financial services, professional services and information services.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FRD vs IOVA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.0M | $86.8M |
| Net Profit | $3.0M | — |
| Gross Margin | 2.3% | 67.4% |
| Operating Margin | 2.3% | -84.7% |
| Net Margin | 1.8% | — |
| Revenue YoY | 78.6% | 17.7% |
| Net Profit YoY | 364.1% | — |
| EPS (diluted) | $0.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.0M | $86.8M | ||
| Q3 25 | $152.4M | $67.5M | ||
| Q2 25 | $134.8M | $60.0M | ||
| Q1 25 | — | $49.3M | ||
| Q4 24 | $94.1M | $73.7M | ||
| Q3 24 | $106.8M | $58.6M | ||
| Q2 24 | $114.6M | $31.1M | ||
| Q1 24 | — | $715.0K |
| Q4 25 | $3.0M | — | ||
| Q3 25 | $2.2M | $-91.3M | ||
| Q2 25 | $5.0M | $-111.7M | ||
| Q1 25 | — | $-116.2M | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-675.0K | $-83.5M | ||
| Q2 24 | $2.6M | $-97.1M | ||
| Q1 24 | — | $-113.0M |
| Q4 25 | 2.3% | 67.4% | ||
| Q3 25 | 1.9% | 43.0% | ||
| Q2 25 | 5.2% | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | -0.2% | 46.2% | ||
| Q2 24 | -1.2% | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 2.3% | -84.7% | ||
| Q3 25 | 1.9% | -140.7% | ||
| Q2 25 | 5.2% | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | -1.3% | -117.5% | ||
| Q3 24 | -0.2% | -152.1% | ||
| Q2 24 | -1.2% | -327.6% | ||
| Q1 24 | — | -16464.6% |
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.5% | -135.3% | ||
| Q2 25 | 3.7% | -186.2% | ||
| Q1 25 | — | -235.5% | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | -0.6% | -142.7% | ||
| Q2 24 | 2.2% | -312.2% | ||
| Q1 24 | — | -15800.8% |
| Q4 25 | $0.43 | — | ||
| Q3 25 | $0.32 | — | ||
| Q2 25 | $0.71 | $-0.33 | ||
| Q1 25 | — | $-0.36 | ||
| Q4 24 | $-0.17 | $-0.24 | ||
| Q3 24 | $-0.10 | $-0.28 | ||
| Q2 24 | $0.37 | $-0.34 | ||
| Q1 24 | — | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $142.2M | $698.6M |
| Total Assets | $311.9M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $297.0M | ||
| Q3 25 | $4.6M | $300.8M | ||
| Q2 25 | $2.1M | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | $1.1M | $323.8M | ||
| Q3 24 | $2.5M | $397.5M | ||
| Q2 24 | $4.1M | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $142.2M | $698.6M | ||
| Q3 25 | $139.3M | $702.3M | ||
| Q2 25 | $137.3M | $698.5M | ||
| Q1 25 | — | $767.9M | ||
| Q4 24 | $127.3M | $710.4M | ||
| Q3 24 | $128.8M | $773.5M | ||
| Q2 24 | $129.7M | $768.5M | ||
| Q1 24 | — | $680.0M |
| Q4 25 | $311.9M | $913.2M | ||
| Q3 25 | $311.3M | $904.9M | ||
| Q2 25 | $219.1M | $907.4M | ||
| Q1 25 | — | $966.7M | ||
| Q4 24 | $210.3M | $910.4M | ||
| Q3 24 | $209.2M | $991.1M | ||
| Q2 24 | $222.8M | $964.3M | ||
| Q1 24 | — | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.7M | $-52.6M |
| Free Cash FlowOCF − Capex | $-6.3M | $-61.9M |
| FCF MarginFCF / Revenue | -3.8% | -71.3% |
| Capex IntensityCapex / Revenue | 1.0% | 10.7% |
| Cash ConversionOCF / Net Profit | -1.56× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.7M | $-52.6M | ||
| Q3 25 | $434.0K | $-78.7M | ||
| Q2 25 | $15.5M | $-67.4M | ||
| Q1 25 | — | $-103.7M | ||
| Q4 24 | — | $-73.3M | ||
| Q3 24 | — | $-59.0M | ||
| Q2 24 | $-6.1M | $-98.4M | ||
| Q1 24 | — | $-122.3M |
| Q4 25 | $-6.3M | $-61.9M | ||
| Q3 25 | $-2.0M | $-89.5M | ||
| Q2 25 | $13.7M | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | $-7.1M | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | -3.8% | -71.3% | ||
| Q3 25 | -1.3% | -132.7% | ||
| Q2 25 | 10.2% | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | -6.2% | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | 1.0% | 10.7% | ||
| Q3 25 | 1.6% | 16.1% | ||
| Q2 25 | 1.3% | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | 0.9% | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | -1.56× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 3.08× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.36× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRD
| Prime Coil | $152.0M | 90% |
| Manufactured Pipe | $14.9M | 9% |
| Customer Owned | $1.1M | 1% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
